Older AdultsAnxiety DisordersSubstance Use Disorders (SUD)SuicidalityMicrodosingPublic Health, Prevention & Behaviour ChangeLSDPsilocybin

Hallucinogen use among young adults ages 19-30 in the United States: Changes from 2018 to 2021

In a longitudinal US cohort of 11,304 young adults aged 19–30 surveyed 2018–2021, past‑year LSD use remained stable (≈3.7% to 4.2%) while non‑LSD hallucinogen use (e.g. psilocybin) roughly doubled from 3.4% to 6.6%. Use was more likely among males, white participants and those from higher socio‑economic backgrounds, and less likely among Black participants and those without a college‑educated parent.

Authors

  • Keyes, K. M.
  • Patrick, M. E.

Published

Addiction
individual Study

Abstract

Background and aimsGiven the shifting landscape of hallucinogen use, particularly with increased therapeutic use, understanding current changes in use is a necessary part of examining the potential risk hallucinogens pose to vulnerable populations, such as young adults. This study aimed to measure hallucinogen use among young adults aged 19–30 years from 2018 to 2021.Design, setting and participantsThis was a longitudinal cohort study among young adults aged 19–30 years from the US general population, interviewed between 2018 and 2021. Participants comprised 11 304 unique respondents, with an average number of follow‐ups of 1.46 (standard deviation = 0.50). Of the observed data points, 51.9% were among females.

Measurements

We examined past 12‐month self‐reported use of lysergic acid diethylamide (LSD), as well as hallucinogens besides LSD (e.g. psilocybin), monitoring any use as well as frequency, overall and by sex.

Findings

From 2018 to 2021, past 12‐month use of LSD among young adults in the US remained relatively unchanged, from 3.7% [95% confidence interval (CI) = 3.1–4.3] in 2018 to 4.2% in 2021 (95% CI = 3.4–5.0). Non‐LSD hallucinogen [e.g. ‘shrooms’, psilocybin or PCP (phenylcyclohexyl piperidine)] use, however, increased in prevalence from 3.4% (95% CI = 2.8–4.1) to 6.6% from 2018 to 2021 (95% CI = 5.5–7.6). Across years, the odds of non‐LSD use were higher for males [odds ratio (OR) = 1.86, 95% CI = 1.52–2.26] and lower for black than white participants (OR = 0.29, 95% CI = 0.19–0.47) and those without a college‐educated parent (OR = 0.80, 95% CI = 0.64–0.99). Demographic disparities were similar for LSD use.

Conclusion

Prevalence of past‐year use non‐lysergic acid diethylamide (LSD) hallucinogen was twice as high in 2021 as in 2018 among US young adults. Correlates of non‐LSD hallucinogen use included being male, white and from higher socio‐economic status backgrounds.

Available with Blossom Pro

Research Summary of 'Hallucinogen use among young adults ages 19-30 in the United States: Changes from 2018 to 2021'

Introduction

Non-medical hallucinogen use is linked with elevated risks including substance use disorders, injury (including self-harm) and anxiety, and young adults are an age group at particularly high risk. The authors note that renewed clinical interest in psychedelic and hallucinogenic compounds — and increasing therapeutic visibility — may reduce perceived harms and expand demand and diversion for non-medical use. Although national surveys suggested increases in some hallucinogen use among US adults in 2018–2019, patterns specifically among young adults and for non-LSD hallucinogens in more recent years remained incompletely described. Keyes and colleagues therefore set out to document changes in past‑12‑month hallucinogen use among US young adults aged 19–30 years from 2018 through 2021. The study aimed to compare trends for LSD and for other hallucinogens (examples given include psilocybin/"shrooms", mescaline, peyote and PCP), to examine frequency of use, and to identify demographic correlates of use over this period. The investigators framed this surveillance as important for public health monitoring given potential increases in non-medical availability and evolving use patterns such as microdosing.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Pro members can view the original manuscript directly in the browser.

Study Details

References (2)

Papers cited by this study that are also in Blossom

The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis

Goldberg, S. B., Pace, B. T., Nicholas, C. R. et al. · Psychiatry Research (2020)

Cited By (3)

Papers in Blossom that reference this study

Post-traumatic stress disorder symptoms following psychedelic use: a naturalistic survey study

Evens, R., Uyar, A., Gosslau, E. et al. · Psychological Medicine (2026)

Epidemiology of Hallucinogen Microdosing Among Young Adults in the United States: A National Study

Keyes, K. M., Terry-McElrath, Y., Patrick, M. E. · Drugs and Alcohol Review (2026)

Personality traits explain the relationship between psychedelic use and less depression in a comparative study

Sjöström, D. K., Claesdotter-Knutsson, E., Kajonius, P. J. · Scientific Reports (2024)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.